SCT to present validated antibody leads against BCMA in a sponsored webinar

Single Cell Technology is sponsoring a webinar hosted by Cambridge Healthtech Institute as a part of their sponsored webinar series. The webinar, titled, "AbTheneum Discovers Rare Hits and Delivers Antibody Metadata: Anti-BCMA Antibody Case Study," will be presenting a number of antibody candidates discovered using SCT's discovery platform.

Dr. Chun-Nan Chen, Chief Scientific Officer at SCT, will be presenting validated antibody candidates demonstrating the power of AbTheneum. "Antibodies from AbTheneum are diverse and we want to be able to show some downstream biophysical and cell-based assay results on the great antibodies we can discover," Dr. Chen commented. The webinar will present a number of promising candidates with activity comparable to other commercially available positive controls and patented leads. The case study data will be followed by demonstration of the flexibility and advantages of AbTheneum. "AbTheneum's phenotypic screening is so flexible, it's really only limited by our creativity," added Dr. Chen.

Currently, AbTheneum can screen antibodies for binding kinetics, epitope binning, cross-reactivity, isotype, subclass determination, and more in development. SCT offers antibody discovery using AbTheneum as a service for pharma and biotech customers and partners. Each project delivers a database of paired heavy and light chain sequences with the corresponding binding activity for each cell screened.

The target for these antibodies is B-cell maturation antigen (BCMA) is a hot target in multiple myeloma treatment and CAR-T therapies. BCMA targeting immunotherapies and BCMA-targeting CAR-T therapies were granted breakthrough status by the FDA in November 2017. Since that time, market activity for Anti-BCMA antibodies has been fervent, with many large and small players.

The webinar will be held on May 8, 2019 at 11AM-12PM ET, and hosted on WebEx by Cambridge Healthtech Institute.
Registration is free, all registrants will be sent a copy of the recording if unable to watch the live broadcast.
Register here
AbTheneum Discovers Rare Hits and Delivers Antibody Metadata: Anti-BCMA Antibody Case Study
Dr. Chun-Nan Chen, Chief Scientific Officer, Single Cell Technology
May 8, 2019, 11AM-12PM ET